RxDoctor Payments Data

Candice Pollard-Reed

Psychiatric/Mental Health · Ashtabula, OHNPI 1205378346

Payments from drug & device makers

$1,022in general payments, 2019–2025

Across 23 payments — averaging $44.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$285
  • E.r. Squibb & Sons, L.L.C.$274
  • AbbVie$158
  • Johnson & Johnson$131
  • Neurocrine Biosciences, Inc.$72
  • Axsome Therapeutics, Inc.$55
  • plus $47 from 1 others

What the payments were for

  • Food & beverage$94793%
  • Education$747%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,022 in reported general payments places this provider in the 60th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$4,702
Medicare patients
28
Services billed
75

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate15$121,492
Invega SustennaPaliperidone Palmitate20$65,851
RexultiBrexpiprazole42$60,473
VraylarCariprazine Hcl24$35,177
AristadaAripiprazole Lauroxil11$28,386
Lurasidone Hcl38$22,795
TrintellixVortioxetine Hydrobromide30$20,236
Aripiprazole111$10,112
Paliperidone ErPaliperidone42$9,105
Duloxetine Hcl132$3,536
Quetiapine Fumarate134$3,030
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine22$2,269
Hydroxyzine Hcl64$1,900
Vilazodone Hcl21$1,868
Buspirone Hcl95$1,852

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$72$121,49215 claims
Johnson & JohnsonInvega Sustenna$131$65,85120 claims
AbbVieVraylar$158$35,17724 claims
Alkermes, Inc.Aristada$285$28,38611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Ashtabula

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →